FrancophonIA/ELRC3.0 huggingface dataset:
English: Laboratoires Takeda, 11-15, quai de Dion Bouton,
Estonian: Prantsusmaa Laboratoires Takeda, 11-15, quai de Dion Bouton, 92816 Puteaux Cedex, Prantsusmaa
English: Parque Norte.Edificio Roble.
Estonian: Hispaania AstraZeneca Farmacéutica Spain, S.A. Parque Norte.Edificio Roble.
English: Viktoriaallee 3-5, 52066 Aachen, Germany
Estonian: 52066 Aachen,
English: LusomedicamentaSociedade Técnica Farmacêutica, S.A. Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal
Estonian: Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A. Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
English: AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Sweden
Estonian: AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Rootsi
English: LusomedicamentaSociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal
Estonian: Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
English: AstraZeneca UK Limited
Estonian: Sloveenia AstraZeneca UK Limited 15 Stanhope Gate
English: Takeda Pharma GmbH,
Estonian: Saksamaa Takeda Pharma GmbH, Viktoriaallee 3-5,
English: Rua Humberto Madeira, 7, Queluz de Baixo 2730-097 Barcarena, Portugal
Estonian: Rua Humberto Madeira, 7, Queluz de Baixo
English: AstraZeneca AB 151 85 Södertälje, Sweden
Estonian: AstraZeneca AB 151 85 Södertälje, Rootsi
English: B-1180 Brussels
Estonian: NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels Belgia
English: Atacand Zid 16mg / 12.5 mg
Estonian: Atacand Zid 16mg / 12.5 mg 16 mg / 12.5 mg
English: AstraZeneca AB, S151 85 Södertälje, Sweden
Estonian: AstraZeneca AB, S-151 85 Södertälje, Rootsi
English: Slovak Republic AstraZeneca AB, S151 85 Södertälje, Sweden
Estonian: Slovakkia AstraZeneca AB, S-151 85 Södertälje, Rootsi
English: Atacand Zid 32 mg / 25 mg
Estonian: Atacand Zid 32 mg / 25 mg 32 mg / 25 mg Tablett
English: Atacand Zid 8 mg / 12.5 mg
Estonian: Atacand Zid 8 mg / 12.5 mg 8 mg / 12.5 mg Tablett
English: AstraZeneca Farmacéutica Spain, S.A.
Estonian: AstraZeneca SpA
English: Ratacand Plus 32 mg / 12.5 mg
Estonian: Atacand Plus 32 mg/12.5 mg
English: Atacand Plus 16/12.5 mg
Estonian: Atacand Plus 16 mg/12.5 mg
English: 16mg/12,5mg comprimé
Estonian: CoKenzen 16mg/12,5mg comprimé
English: Atacand Plus 16 + 12.5 mg
Estonian: Atacand Plus 16 + 12.5 mg 16 mg / 12.5 mg
English: Ratacand Plus 32 mg / 25 mg
Estonian: Atacand Plus Forte 32 mg/25 mg
English: Atacand Plus 16/12,5 mg
Estonian: Atacand Plus 16/12,5 mg 16 mg / 12.5 mg
English: 32mg/25mg comprimidos
Estonian: Parapres Plus Forte 32mg/25mg comprimidos
English: Blopress Plus 32mg/ 12,5mgTabletten
Estonian: Blopress Plus 32mg/ 12,5mg - Tabletten
English: Blopress Plus 16mg/12.5mgTabletten
Estonian: Blopress Plus 16mg/12.5mg - Tabletten
English: The European Commission granted a marketing authorisation valid throughout the European Union for Hexyon on 17 April 2013.
Estonian: Euroopa Komisjon andis Hexyoni müügiloa, mis kehtib kogu Euroopa Liidus, 17. aprillil 2013.
English: What measures are being taken to ensure the safe and effective use of Hexyon?
Estonian: Mis meetmed võetakse, et tagada Hexyoni ohutu ja efektiivne kasutamine?
English: The full EPAR for Hexyon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Hexyoni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Vaccination with Hexyon should be carried out according to official recommendations.
Estonian: Vaktsineerimine Hexyoniga peab toimuma vastavalt ametlikele soovitustele.
English: Other information about Hexyon
Estonian: Muu teave Hexyoni kohta
English: These materials have been inactivated where necessary so that they do not cause any disease.
Estonian: Kus asjakohane, on viirusmaterjal inaktiveeritud, et see ei põhjustaks haigust.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Hexyoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What is Hexyon and what is it used for?
Estonian: Mis on Hexyon ja milleks seda kasutatakse?
English: Why is Hexyon approved?
Estonian: Miks Hexyon heaks kiideti?
English: Hexyon contains small amounts of materials derived from the bacteria and viruses it protects against.
Estonian: Hexyon sisaldab väheses koguses materjali, mis pärineb bakteritest ja viirustest, mille vastu see kaitseb.
English: This means that some of the active substances are fixed onto aluminium compounds, to stimulate a better response.
Estonian: See tähendab, et mõni toimeaine on parema immuunvastuse tekitamiseks kinnitatud alumiiniumiühenditele.
English: Hexyon is a vaccine.
Estonian: Hexyon on vaktsiin.
English: It is not intended to provide practical advice on how to use Hexyon.
Estonian: Hindamisaruandes ei anta Hexyoni kasutamise praktilisi nõuandeid.
English: What are the risks associated with Hexyon?
Estonian: Mis riskid Hexyoniga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Hexyon.
Estonian: See on vaktsiini Hexyon Euroopa avaliku hindamisaruande kokkuvõte.
English: Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local vaccination schedules.
Estonian: Hexyoni on mitmes riigis kogu maailmas uuritud 12 põhiuuringus, milles osales üle 3400 lapse vanuses 6 nädalat kuni 2 aastat, kellele manustati kohalike vaktsineerimisskeemide järgi esimese kuue elukuu vältel kolm vaktsiiniannust.
English: It must not be used in children who have an uncontrolled or severe illness affecting the brain or nervous system, such as uncontrolled epilepsy, unless the condition has stabilised with treatment and the benefit clearly outweighs the risk.
Estonian: Samuti ei tohi seda kasutada lastel, kellel on ohjamata või raske aju- või närvisüsteemi haigus, näiteks ohjamata epilepsia (langetõbi, mida ei ravita), välja arvatud juhul, kui lapse seisund on sobiva raviga stabiliseerunud ja vaktsineerimise kasulikkus on selgelt suurem kui selle riskid.
English: It is used in babies and toddlers aged from six weeks to protect against the following infectious diseases:
Estonian: Hexyoni kasutatakse alates 6 nädala vanuste imikute ja väikelaste kaitsmiseks järgmiste nakkushaiguste eest:
English: Regarding safety, the CHMP considered that Hexyon's overall safety profile is similar to other vaccines, although vaccination with Hexyon is more likely than similar vaccines to cause reactions (mainly at the injection site).
Estonian: Ohutuse kohta järeldas inimravimite komitee, et Hexyoni ohutusprofiil on kokkuvõttes teiste vaktsiinidega sarnane, kuigi Hexyoniga vaktsineerimine tekitab sarnaste vaktsiinidega võrreldes suurema tõenäosusega reaktsioone (eelkõige süstekohas).
English: Hexyon is given by deep injection into a muscle, normally in the upper thigh or the shoulder.
Estonian: Hexyoni süstitakse sügavale lihasesse tavaliselt reie ülaossa või õlalihasesse.
English: How does Hexyon work?
Estonian: Kuidas Hexyon toimib?
English: Hexyon must not be used in children who have ever had an allergic reaction to Hexyon or a vaccine containing the same components, including substances used during the manufacture of the vaccine and which may be found at extremely low levels (such as the antibiotics neomycin or streptomycin).
Estonian: Hexyoni ei tohi kasutada lastel, kellel on kunagi tekkinud raske allergiline reaktsioon Hexyoni või samu komponente sisaldavate vaktsiinide suhtes, sh vaktsiinide tootmisel kasutatud ainete suhtes, mille sisaldus võib olla äärmiselt väike, näiteks antibiootikumid neomütsiin ja streptomütsiin.
English: The studies showed that protective antibody levels against the various diseases developed in between 90 and 100% of children after the first three doses of Hexyon; protection was maintained or improved when a booster dose was given.
Estonian: Nendes uuringutes selgus, et haiguste vastane antikehade sisaldus tekkis esimese kolme Hexyoni annuse manustamise järel 90-100%-l lastest; revaktsineerimisannuse järel kaitse säilis või paranes.
English: Hexyon or an appropriate combination of other vaccines can be used for the booster dose.
Estonian: Revaktsineerimiseks võib kasutada Hexyoni või asjakohast muude vaktsiinide kombinatsiooni.
English: How is Hexyon used?
Estonian: Kuidas Hexyoni kasutatakse?
English: The most common side effects with Hexyon include pain and redness at the site of injection, irritability and crying.
Estonian: Hexyoni kõige sagedamad kõrvalnähud on süstekoha valu ja punetus, samuti ärrituvus ja nutmine.
English: For practical information about using Hexyon, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Hexyoni kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The recommended initial vaccination schedule is either two doses, given two months apart or three doses, given at least one month apart.
Estonian: Soovitatava vaktsineerimiskava kohaselt manustatakse 2 algannust 2-kuuse ajavahemikuga või 3 algannust 1kuuse ajavahemikuga.
English: For the full list of all side effects reported with Hexyon, see the package leaflet.
Estonian: Hexyoni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: These studies showed that Hexyon produces similar antibody profiles over time to comparable vaccines, and that the vaccine can be given at the same time as Prevenar and Rotarix.
Estonian: Uuringud tõendasid, et Hexyon tekitas aja jooksul võrdlusvaktsiinidega samasuguse antikehade sisalduse profiili ning et Hexyoni tohib manustada koos Prevenari ja Rotarixiga.
English: Hexyon is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type b bacteria, the hepatitis B virus, and inactivated polioviruses.
Estonian: Hexyon on vaktsiin, mille toimeained on saadud difteeria, teetanuse, läkaköha ja Haemophilus influenzae b-tüübi bakteritest, B-hepatiidi viirusest ning inaktiveeritud polioviirustest.
English: For more information about treatment with Hexyon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Hexyoniga toimuva vaktsineerimise kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hexyon have been included in the summary of product characteristics and the package leaflet.
Estonian: Hexyoni omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It must not be used in children who have ever had encephalopathy (a brain disease) of unknown cause within seven days of receiving a vaccine containing pertussis components in the past.
Estonian: Hexyoni ei tohi kasutada lastel, kellel on varem tekkinud 7 ööpäeva jooksul pärast läkaköha haigustekitajate komponente sisaldava vaktsiiniga vaktsineerimist teadaoleva põhjuseta entsefalopaatia (teatud ajuhaigus).
English: What benefits of Hexyon have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Hexyoni kasulikkus?
English: In the study, children who either received Hexyon produced a similar antibody response to those who received a comparator vaccine (Infanrix hexa), when given as a two-dose schedule followed by a booster 6 months later.
Estonian: Hexyoniga vaktsineeritud lastel tekkis sarnane antikehavastus kui võrdlusvaktsiini (Infarix hexa) saanud lastel, kui neid vaktsineeriti kaheannuselise skeemi alusel, millele järgnes 6 kuu pärast revaktsineerimine.
English: Vaccination with Hexyon should be postponed if a child has a moderate to severe fever.
Estonian: Mõõduka või kõrge palaviku korral tuleb Hexyoniga vaktsineerimine edasi lükata.
English: The CHMP noted that Hexyon has been shown to produce protective antibody levels against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and H. influenzae type b infections in children between six weeks and two years of age regardless of ethnicity.
Estonian: Inimravimite komitee märkis, et Hexyoni manustamise järel tekib 6-nädalastel kuni 2-aastastel lastel etnilisest päritolust sõltumata difteeria, teetanuse, läkaköha, B-hepatiidi viiruse, polioviiruste ja Haemophilus influenzae b-tüübi bakterite vastu kaitsev antikehade tase.
English: A subsequent study involving 455 children looked at the longer-term persistence of protective antibodies up to 3 years after a booster dose with Hexyon, and another study in 1,336 children evaluated the response to different lots of the vaccine and what happened when it was given with vaccines for infections caused by the bacterium Streptococcus pneumoniae (Prevenar) and rotavirus (Rotarix).
Estonian: Veel ühes uuringus, millel osales 1336 last, hinnati immuunvastust eri vaktsiinipartiidele, samuti Hexyoni manustamist koos bakteri Streptococcus pneumoniae ja rotaviiruse põhjustatud haiguste vastaste vaktsiinidega (vastavalt Prevenar ja Rotarix).
English: The effects were compared with a combination of separate vaccines designed to protect against the diseases included in Hexyon.
Estonian: Hexyoni toimet võrreldi samade haiguste vastu väljatöötatud eri vaktsiinide kombinatsiooniga.
English: The immune system will then be able to produce antibodies quickly when the person is naturally exposed to the bacteria or viruses.
Estonian: Kui inimene puutub nende bakterite või viirustega hiljem looduslikult kokku uuesti, tekivad organismis antikehad kiiremini.
English: Hexyon is available as a suspension for injection in vials and prefilled syringes.
Estonian: Seda turustatakse süstelahusena viaalides või eeltäidetud süstaldes.
English: Lynparza received a marketing authorisation valid throughout the EU on 16 December 2014.
Estonian: Lynparza on saanud müügiloa, mis kehtib kogu ELis, 16. detsembril 2014.
English: What measures are being taken to ensure the safe and effective use of Lynparza?
Estonian: Mis meetmed võetakse, et tagada Lynparza ohutu ja efektiivne kasutamine?
English: Further information on Lynparza can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lynparza.
Estonian: Lisateave Lynparza kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/lynparza.
English: Lynparza (olaparib)
Estonian: Lynparza (olapariib)
English: Treatment is continued for as long as the disease is not getting worse.
Estonian: Ravi jätkatakse seni, kuni haigus ei süvene.
English: Lynparza is available as tablets (100 and 150 mg) and capsules (50 mg) which the patient takes twice a day.
Estonian: Lynparzat turustatakse tablettidena (100 mg ja 150 mg) ja kapslitena (50 mg), mida patsient võtab 2 korda ööpäevas.
English: The side effects with Lynparza were mostly mild or moderate and were generally manageable.
Estonian: Lynparza täheldatud kõrvalnähud olid enamasti kerged või mõõdukad ja üldiselt hallatavad.
English: The European Medicines Agency therefore decided that Lynparza's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Lynparza kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Furthermore, while tablets can be taken with food or between meals, the patient should take the capsules at least 1 hour after food and not eat for up to 2 hours afterwards.
Estonian: Tablette saab võtta toiduga või söögikordade vahel, kuid kapsleid peab võtma vähemalt 1 tund pärast sööki ning seejärel ei tohi 2 tundi süüa.
English: Other information about Lynparza
Estonian: Muu teave Lynparza kohta
English: As for all medicines, data on the use of Lynparza are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Lynparza kasutamise kohta pidevat järelevalvet.
English: What is Lynparza and what is it used for?
Estonian: Mis on Lynparza ja milleks seda kasutatakse?
English: The most common side effects with Lynparza (which may affect more than 1 in 10 people) are tiredness, nausea (feeling sick), vomiting, diarrhoea, dyspepsia (heartburn), cough, headache, dysgeusia (taste disturbances), decreased appetite, dizziness, upper abdominal pain (stomach ache), dyspnoea (difficulty breathing), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and thrombocytopenia (low blood platelet counts).
Estonian: Lynparza kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on väsimus, iiveldus, oksendamine, kõhulahtisus, düspepsia (kõrvetised), köha, peavalu, maitsehäired, isutus, peapööritus, ülakõhuvalu, düspnoe (hingamisraskused), aneemia (erütrotsüütide ehk vere punaliblede vähesus), leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus) ja trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lynparza have also been included in the summary of product characteristics and the package leaflet.
Estonian: Lynparza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Why is Lynparza authorised in the EU?
Estonian: Miks Lynparza ELis heaks kiideti?
English: The company that markets Lynparza will carry out studies to further confirm the benefit, including long-term benefit, of the medicine in patients with ovarian cancer.
Estonian: Lynparza turustaja korraldab uuringud, et täiendavalt kinnitada ravimi kasulikkust (sh pikaajalist kasulikkust) munasarjavähiga patsientidel.
English: Side effects reported with Lynparza are carefully evaluated and any necessary action taken to protect patients.
Estonian: Lynparza kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: For more information about using Lynparza, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Lynparza kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Therefore, when PARP proteins are blocked, the damaged DNA in cancer cells cannot be repaired, and, as a result, the cancer cells die.
Estonian: Kui PARP-valgud on blokeeritud, ei saa need vähirakkudes parandada kahjustatud DNA-d, mille tulemusel vähirakud hävivad.
English: In advanced ovarian cancer, the doctor may stop treatment after 2 years if X-rays show no signs of the cancer.
Estonian: Kaugelearenenud munasarjavähi korral võib arst 2 aasta pärast ravi lõpetada, kui röntgenuuringul puudub vähileid.
English: Lynparza contains the active substance olaparib.
Estonian: Lynparza sisaldab toimeainena olapariibi.
English: What are the risks associated with Lynparza?
Estonian: Mis riskid Lynparzaga kaasnevad?
English: Lynparza can increase the time these patients live without their disease getting worse.
Estonian: Lynparza võib pikendada nende patsientide progresseerumiseta elumust.
English: The doses in milligrams are different for the tablets and capsules.
Estonian: Tablettide ja kapslite annused milligrammides on erinevad.
English: Studies show that Lynparza increases the time patients live without their disease getting worse after treatment with platinum-based chemotherapy has reduced or cleared the cancer:
Estonian: Uuringud tõendavad, et Lynparza pikendab patsientide progresseerumiseta elumust (aega, kui patsiendid elavad haiguse süvenemiseta) pärast seda, kui vähkkasvaja on plaatinapõhise keemiaraviga vähenenud või kadunud.
English: How does Lynparza work?
Estonian: Kuidas Lynparza toimib?
English: Treatment may be interrupted or stopped or the dose reduced if certain side effects develop.
Estonian: Teatud kõrvalnähtude tekkimisel tohib ravi katkestada või lõpetada või vähendada ravimi annust.
English: For the full list of side effects and restrictions with Lynparza, see the package leaflet.
Estonian: Lynparza kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Lynparza was effective in a study involving 302 patients with HER2-negative breast cancer with BRCA1/2 mutations whose cancer had spread.
Estonian: Lynparza oli efektiivne uuringus, milles osales 302 geenide BRCA1/2 mutatsioonidega ja HER2-negatiivse metastaseerunud rinnavähiga patsienti.
English: • treatment of breast cancer which is HER2-negative and that has spread beyond the original site in patients with mutations in BRCA1 or BRCA2 genes who have been treated with certain breast cancer medicines (unless these medicines were not suitable).
Estonian: • HER2-negatiivse vähi ravi, kui vähk on levinud algpaikmest kaugemale, patsientidel, kellel esinevad mutatsioonid BRCA1 või BRCA2 geeni(de)s ja keda on ravitud rinnavähi teatud ravimitega (v.a kui need ravimid ei olnud sobivad).
English: Patients treated with Lynparza lived on average 7.0 months without their disease getting worse compared with 4.2 months for patients treated with the doctor's choice of another cancer medicine.
Estonian: Lynparzaga ravitud patsientide progresseerumiseta elumus oli keskmiselt 7,0 kuud ja arsti valikul muud vähiravimit kasutanud patsientidel 4,2 kuud.
English: The dose and the choice between capsules and tablets of Lynparza depends on what disease it is being used for.
Estonian: Lynparza annus ja see, kas kasutatakse kapsleid või tablette, sõltub ravitavast haigusest.
English: • In a third study involving 391 patients with advanced cancer who had BRCA1/2 mutations, the disease had not got worse in around 74% of patients who took Lynparza for 2 years compared with 35% of patients on placebo.
Estonian: • Kolmandas uuringus, milles osales 391 kaugelearenenud vähiga patsienti, kellel esinesid geenide BRCA1/2 mutatsioonid, oli Lynparzat kasutanud patsientidest neid, kellel haigus ei süvenenud, ligikaudu 74% ja platseebot kasutanutest 35%.
English: Lynparza can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Estonian: Ravi peab alustama ja jälgima vähiravimite kasutamises kogenud arst.
English: Women must not breastfeed during treatment with Lynparza and for a month after stopping treatment.
Estonian: Lynparza-ravi ajal ja vähemalt 1 kuu pärast ravi lõppu ei tohi naispatsiendid imetada.
English: How is Lynparza used?
Estonian: Kuidas Lynparzat kasutatakse?
English: − in newly diagnosed women with advanced cancer with mutations (changes) in one or both genes known as BRCA1 and BRCA2 who have been treated with platinum-based chemotherapy and in whom this treatment has reduced or cleared the cancer;
Estonian: − naistel, kellel esineb esmakordselt diagnoositud kaugelearenenud vähk koos mutatsioonidega (muutustega) ühes või mõlemas vähiga seotud geenis (BRCA1 ja BRCA2) ja kes on saanud plaatinapõhist keemiaravi ning kellel pärast seda ravi on vähkkasvaja vähenenud või kadunud;
English: − women whose cancer had come back (relapsed) after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancer;
Estonian: − naistel, kellel pärast varasemat ravi on vähk taastekkinud (vähi relaps) ja kellel pärast plaatinapõhist ravi on vähkkasvaja vähenenud või kadunud;
English: An overview of Lynparza and why it is authorised in the EU
Estonian: Ülevaade ravimist Lynparza ja ELis müügiloa väljastamise põhjendus